ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting
30 Abril 2019 - 6:00AM
ImprimisRx, the ophthalmology-focused pharmaceutical compounding
subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced
its participation at the American Society of Cataract and
Refractive Surgery (ASCRS) Annual Meeting to be held at the San
Diego Convention Center in San Diego, CA May 3-7, 2019. With an
estimated 11,000 attendees expected, this is the largest U.S.
meeting of anterior segment surgeons, which integrates a scientific
program dedicated to the needs of surgeons, specialists, practice
management staff, and ophthalmic technicians and nurses.
At the conference, attendees will have the
opportunity to meet with ImprimisRx representatives at Exhibit
#1427 to learn more about new ImprimisRx proprietary formulations
launching this year, including:
- Klarity-A™ Drops (preservative-free ophthalmic solution +
azithromycin 1%)
- Klarity-B™ Drops (preservative-free ophthalmic solution +
betamethasone 0.1%)
- Klarity-L™ Drops (preservative-free ophthalmic solution +
loteprednol 0.5%)
- LessDrops® formulations with moxifloxacin
- Povidone Iodine 5%
There will be a combination of eleven relevant
physician presentations or posters, which will touch on all five
ImprimisRx portfolios: Dropless®, LessDrops, Simple Drops®, Total
Tears®, and IV Free®. Additionally, ImprimisRx is hosting an open
house at the Hard Rock Hotel in downtown San Diego from 5:30-7:30pm
on Saturday May 4th, where anyone registered can learn more about
the robust portfolio of ophthalmic compound medications offered by
ImprimisRx. Please register by clicking here if you have an
interest in attending the open house.
John Saharek, President of ImprimisRx,
commented, “We are excited to have our largest presence ever at
ASCRS, where paper presentations, posters, speakers, and an
instructional course will detail the value proposition of our
unique portfolio. ImprimisRx is also announcing the launch of a
number of new ophthalmology-focused innovative compounded
formulations, some of which represent completely new markets for
us. Our team is excited to update the ophthalmic community on our
unique offerings which we believe address unmet needs. We look
forward to visiting with customers and shareholders alike at
Exhibit #1427.”
About ImprimisRx
ImprimisRx is the nation’s leading ophthalmology
compounding business, serving thousands of ophthalmologists and
optometrists in all 50 states, with more than 20 proprietary
ophthalmic formulations. ImprimisRx is headquartered in San Diego,
CA and owns two FDA-inspected production and dispensing facilities
in Ledgewood, New Jersey. There have been over one million eyes
served by the formulations produced at these facilities.
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) owns a
portfolio of healthcare businesses, including the nation’s leading
ophthalmology pharmaceutical compounding business, ImprimisRx. The
company holds large equity positions in Eton Pharmaceuticals,
Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield
Pharmaceuticals and Radley Pharmaceuticals, all companies founded
as subsidiaries of Harrow Health. The Company also owns royalty
rights in certain 505(b)(2) drug candidates being developed by
Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create,
invest in and grow paradigm shifting health care businesses that
put patients first. For more information about Harrow Health,
please visit the Investor Relations section of the corporate
website by clicking here.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Harrow Health’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Such documents may be read free of
charge on the SEC's web site at www.sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. Except as required by law, Harrow Health
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
No ImprimisRx compounded formulation is
FDA-approved. All ImprimisRx formulations are
customizable. Other than drugs compounded at a registered
outsourcing facility, all ImprimisRx compounded formulations
require a prescription for an individually identified patient
consistent with federal and state laws.
All educational content of the ASCRS•ASOA Annual
Meeting is planned by its program committee, and ASCRS•ASOA does
not endorse, promote, approve, or recommend the use of any
products, devices, or services.
Investor Contact:Jon
Pattonjpatton@harrowinc.com 858-704-4587
Media Contact:Deb HollidayHolliday
Communications, Inc.deb@hollidaycommunications.net412.877.4519
Source: Harrow Health, Inc.
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024